menu
    • menu

    Company profile for Curasight

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types, most notably for risk stratification in prostate cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CurasightDenmark Flag
    Country
    Country
    Denmark
    Address
    Address
    Ole Maaløes Vej 3 DK-2200 København N
    Telephone
    Telephone
    +45 22 83 01 60
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.curasight.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Curasight Opens Enrollment in uTREAT Phase 1 Brain Cancer Trial
    Curasight Opens Enrollment in uTREAT Phase 1 Brain Cancer Trial

    26 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curasights-utreat-phase-1-trial-in-brain-cancer-now-open-for-patient-enrollment-302626494.html

    PR NEWSWIRE
    26 Nov 2025
    Share Share
    Curasight Gets CTA Nod for Ph1 uTREAT Trial in Brain Cancer
    Curasight Gets CTA Nod for Ph1 uTREAT Trial in Brain Cancer

    26 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curasight-announces-acceptance-of-clinical-trial-application-cta-for-phase-1-trial-with-utreat-in-brain-cancer-patients-302538481.html

    PR NEWSWIRE
    26 Aug 2025
    Share Share
    Curasight A/S Achieves First Milestone under collaboration with Curium Inc.
    Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

    22 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curasight-as-achieves-first-milestone-under-collaboration-with-curium-inc-302040336.html

    PR NEWSWIRE
    22 Jan 2024
    Share Share
    Curasight A/S reports positive preclinical results with uTREAT
    Curasight A/S reports positive preclinical results with uTREAT

    07 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curasight-as-reports-positive-preclinical-results-with-utreat-in-aggressive-brain-cancer-glioblastoma-301844654.html

    PR NEWSWIRE
    07 Jun 2023
    Share Share
    Curasight and Curium announce global partnership for uTRACE® in prostate cancer
    Curasight and Curium announce global partnership for uTRACE® in prostate cancer

    01 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curasight-and-curium-announce-global-partnership-for-utrace-in-prostate-cancer-301812582.html

    PR NEWSWIRE
    01 May 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search